Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

OBJECTIVE: To investigate the efficacy and safety of the interleukin-6 receptor antibody tocilizumab in patients with Takayasu arteritis (TAK). METHODS: Patients with TAK who had relapsed within the previous 12 weeks were induced into remission with oral glucocorticoid therapy. In this double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakaoka, Yoshikazu, Isobe, Mitsuaki, Takei, Syuji, Tanaka, Yoshiya, Ishii, Tomonori, Yokota, Shumpei, Nomura, Akira, Yoshida, Seitaro, Nishimoto, Norihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867398/
https://www.ncbi.nlm.nih.gov/pubmed/29191819
http://dx.doi.org/10.1136/annrheumdis-2017-211878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867398/
https://www.ncbi.nlm.nih.gov/pubmed/29191819
http://dx.doi.org/10.1136/annrheumdis-2017-211878

Ejemplares similares